DIGdata: DIG NHLBI Teaching Dataset

Description Format Source References Examples

Description

A clinical trial focused dataset was developed using the Digitalis Investigation Group (DIG). This dataset was designed to replicate the results found in the February 1997 New England Journal of Medicine article. Note that statistical processes such as permutations within treatment groups were used to completely anonymize the data; therefore, inferences derived from the teaching dataset may not be valid. The DIG Trial was a randomized, double-blind, multicenter trial with more than 300 centers in the United States and Canada participating. The purpose of the trial was to examine the safety and efficacy of Digoxin in treating patients with congestive heart failure in sinus rhythm. Data on 5281 male and 1519 female collected.

Format

This data frame contains the following columns:

ID

Patient ID

TRTMT

(0=Placebo, 1=Treatment)

AGE

Calculated: age at randomization

RACE

Q5: Race, 1=White 2=Nonwhite

SEX

(1 = male or 2 = female)

EJFPER

Q3: Ejection fraction (percent)

EJFMETH

Q3A: Ejection Fraction method

CHESTX

Q6: Chest X-ray (CT-Ratio)

BMI

Calculated: Body Mass Index (kg per M-squared)

KLEVEL

Q9A: Serum Potassium level

CREAT

Q9: Serum Creatinine (mg per dL)

DIGDOSER

Q10: Recommended Digoxin dose

CHFDUR

Q12: Duration of CHF (months)

RALES

Q13: Rales

ELEVJVP

Q14: Elevated jugular venous pressure

PEDEMA

Q15: Peripheral Edema

RESTDYS

Q16: Dyspnea at Rest

EXERTDYS

Q17: Dyspnea on Exertion

ACTLIMIT

Q18: Limitation of activity

S3

Q19: S3 Gallop

PULCONG

Q20: Pulmonary congestion

NSYM

Calculated: Sum of Q13-Q20, Y or N status

HEARTRTE

Q21: Heart Rate (beats per min)

DIABP

Q22: Diastolic BP (mmHg)

SYSBP

Q22: Sysolic BP (mmHg)

FUNCTCLS

Q23: NYHA Functional Class

CHFETIOL

Q24: CHF Etiology

PREVMI

Q25: Previous Myocardial Infarction

ANGINA

Q26: Current Angina

DIABETES

Q27: History of Diabetes

HYPERTEN

Q28: History of Hypertension

DIGUSE

Q29: Digoxin within past week

DIURETK

Q30: Potassium sparing Diuretics

DIURET

Q31: Other Diuretics

KSUPP

Q31A: Potassium supplements

ACEINHIB

Q32: Ace inhibitors

NITRATES

Q33: Nitrates

HYDRAL

Q34: Hydralazine

VASOD

Q35: Other Vasodilators

DIGDOSE

Q36: Dose of Digoxin per Placebo prescribed

CVD

Hosp: Cardiovascular Disease

CVDDAYS

Days randomization to First CVD Hosp

WHF

Hosp: Worsening Heart Failure

WHFDAYS

Days randomization to First WHF Hosp

DIG

Hosp: Digoxin Toxicity

DIGDAYS

Days rand. to First Digoxin Tox Hosp

MI

Hosp: Myocardial Infarction

MIDAYS

Days randomization to First MI Hosp

UANG

Hosp: Unstable Angina

UANGDAYS

Days rand. to First Unstable Angina Hosp

STRK

Hosp: Stroke

STRKDAYS

Days randomization to First Stroke Hosp

SVA

Hosp: Supraventricular Arrhythmia

SVADAYS

Days rand. to First SupraVent Arr. Hosp

VENA

Hosp: Ventricular Arrhythmia

VENADAYS

Days rand. to First Vent. Arr. Hosp

CREV

Hosp: Coronary Revascularization

CREVDAYS

Days rand. to First Cor. Revasc.

OCVD

Hosp: Other Cardiovascular Event

OCVDDAYS

Days rand. to First Other CVD Hosp

RINF

Hosp: Respiratory Infection

RINFDAYS

Days rand. to First Resp. Infection Hosp

OTH

Hosp: Other noncardiac, nonvascular

OTHDAYS

Days rand. to 1st Other Non CVD Hosp

HOSP

Hosp: Any Hospitalization

HOSPDAYS

Days randomization to First Any Hosp

NHOSP

Number of Hospitalizations

DEATH

Vital Status of Patient 1=Death 0=Alive

DEATHDAY

Days till last followup or death

REASON

Cause of Death

DWHF

Primary Endpt: Death or Hosp from HF

DWHFDAYS

Days rand. to death or Hosp from WHF

Source

NHLBI Teaching Dataset

References

The effect of digoxin on mortality and morbidity in patients with heart failure . The Digitalis Investigation Group. N En gl J Med. 1997 Feb 20;336(8):525-33

Examples

1

asympTest documentation built on May 2, 2019, 11:16 a.m.